Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Alice, Cuenant"'
2
Akademický článek
High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor
Autor: Hadjer Dellal, Abdelhay Boulahtouf, Elina Alaterre, Alice Cuenant, Marina Grimaldi, William Bourguet, Céline Gongora, Patrick Balaguer, Philippe Pourquier
Publikováno v: Cells, Vol 9, Iss 6, p 1469 (2020)
Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease. Inhi
Externí odkaz: https://doaj.org/article/6f17935324c14c019d86b52251621318
Zobrazit plný text záznamu
3
[Development of a therapeutic education program for prostate cancer patients undergoing new generation hormone therapy]
Autor: Alice, Cuenant, Isabelle, Eglin, Virginia, Ferreira, Nadine, Houédé
Publikováno v: Bulletin du cancer. 109(5)
New generation hormone therapies (NGHT) is the gold standard treatment for metastatic prostate cancers and/or castration-resistant tumors. Four molecules have been approved: enzalutamide, abiraterone acetate, apalutamide and darolutamide. These treat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::29dae60a930003e99d85878f1a24ec4f
https://pubmed.ncbi.nlm.nih.gov/35027162
Zobrazit plný text záznamu
4
High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor
Autor: Alice Cuenant, Hadjer Dellal, Elina Alaterre, Philippe Pourquier, Marina Grimaldi, William Bourguet, Abdelhay Boulahtouf, Céline Gongora, Patrick Balaguer
Publikováno v: Cells
Cells, MDPI, 2020, 9 (6), pp.1469. ⟨10.3390/cells9061469⟩
Cells, Vol 9, Iss 1469, p 1469 (2020)
Cells, 2020, 9 (6), pp.1469. ⟨10.3390/cells9061469⟩
Volume 9
Issue 6
Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease. Inhi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d29941432f4cb78e8ad5cee9b766c98
https://hal.archives-ouvertes.fr/hal-03003926
Zobrazit plný text záznamu
5
Clinical Relevance of Routine Monitoring of Patient-reported Outcomes Versus Clinician-reported Outcomes in Oncology
Autor: Alice Cuenant, Mireille Favier, Frédéric Fiteni, Christelle Cousin, Nadine Houede
Publikováno v: In Vivo
In Vivo, International Institute of Anticancer Research (IIAR), 2019, 33 (1), pp.17-21. ⟨10.21873/invivo.11433⟩
International audience; The National Cancer Institute Common Terminology Criteria for Adverse Events classification is the standard classification used by the physicians in oncology for reporting adverse events. This classification has evolved over t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3efed58b69b0b49eeeb4eead6388d35e
https://hal.umontpellier.fr/hal-02419826
Zobrazit plný text záznamu
6
Clinical Relevance of Routine Monitoring of Patient-reported Outcomes
Autor: Frederic, Fiteni, Alice, Cuenant, Mireille, Favier, Christelle, Cousin, Nadine, Houede
Publikováno v: In vivo (Athens, Greece). 33(1)
The National Cancer Institute Common Terminology Criteria for Adverse Events classification is the standard classification used by the physicians in oncology for reporting adverse events. This classification has evolved over the last years according
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1baa3898d0a339dd6e727b3e30274f20
https://pubmed.ncbi.nlm.nih.gov/30587597
Zobrazit plný text záznamu
7
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
Autor: Anna Durigova, Alice Cuenant, Krisztian Homicsko, Marie Vinches, Nadia Hayaoui, Marie Alexandre, Marie Viala, Luca Gianni, Diego Tosi, Céline Gongora, Caroline Mollevi
Publikováno v: British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2018, 118 (5), pp.679-697. ⟨10.1038/bjc.2017.473⟩
British journal of cancer, vol. 118, no. 5, pp. 679-697
International audience; BACKGROUND: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined.METHODS: We identifi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03f0a204474d74cee7ad53b33df4109
https://hal.umontpellier.fr/hal-02292921
Zobrazit plný text záznamu
8
Strategies for clinical development of monoclonal antibodies beyond first-in-man trials: Tested doses and rationale for dose selection
Autor: Diego Tosi, Caroline Mollevi, Marie Vinches, Luca Gianni, Alice Cuenant, Nadia Hayaoui, Anna Durigova, Marie Alexandre
Publikováno v: Journal of Clinical Oncology. 33:3040-3040
3040 Background: We conducted a comprehensive survey (J. Clin. Oncol., in press) on the design, implementation and outcome of first-in-human trials (FIHT) of monoclonal antibodies (mAbs) over the l...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35cb31dee872fe3a56cb95e72ca9dacb
https://doi.org/10.1200/jco.2015.33.15_suppl.3040
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje